crispr-therapeutics-ag-pipeline-potenzial-in-der-kardiologie - Stock Newsroom

S TOCK newsroom .COM

S&P 500 6,823 +0.59%

DJIA 48,236 +0.68%

Nasdaq 25,030 +0.55%

DAX 23,866 -0.41%

Gold $4,196 +0.16%

Oil $97.89 +1.24%

BTC $71,849 +0.68%

VIX 20.68 -14.82%

EUR/USD 1.1785 -0.02%

ETH $2,206 -0.13%

S&P 500 6,823 +0.59%

DJIA 48,236 +0.68%

Nasdaq 25,030 +0.55%

DAX 23,866 -0.41%

Gold $4,196 +0.16%

Oil $97.89 +1.24%

BTC $71,849 +0.68%

VIX 20.68 -14.82%

EUR/USD 1.1785 -0.02%

ETH $2,206 -0.13%

crispr-therapeutics-ag-pipeline-potenzial-in-der-kardiologie

High-tech cardiology lab visualizing CRISPR Therapeutics Pipeline gene edits for cholesterol and Lp(a).

CRISPR Therapeutics Pipeline +3.2%: Cardiology Boom Risk

By Maik Kemper • Apr 8, 2026

High-tech cardiology lab visualizing CRISPR Therapeutics Pipeline gene edits for cholesterol and Lp(a).

CRISPR Therapeutics Pipeline +3.2%: Cardiology Boom Risk

By Maik Kemper • Apr 8, 2026

Can the CRISPR Therapeutics Pipeline in cardiology turn today’s modest gene-editing revenues into a multi-billion-dollar growth story? Maik Kemper Editor in Chief Conclusion In summary,…